These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2287309)

  • 21. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
    Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
    Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [International study of the effect of dexfenfluramine in obesity (ISIS): 6 months' results].
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Rev Med Interne; 1989; 10(3):271-7. PubMed ID: 2669089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
    Miller KJ
    Mol Interv; 2005 Oct; 5(5):282-91. PubMed ID: 16249524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between health-related quality of life and weight loss.
    Kolotkin RL; Crosby RD; Williams GR; Hartley GG; Nicol S
    Obes Res; 2001 Sep; 9(9):564-71. PubMed ID: 11557837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of obesity with fenfluramine.
    Schindler H; Bielesz G
    Wien Med Wochenschr; 1975 Jan; 125(5):85-8. PubMed ID: 1124579
    [No Abstract]   [Full Text] [Related]  

  • 27. [Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].
    Del Ponte A; D'Orazio N; Di Giacomo G; Tritella T; Bitti G; Martines G
    Recenti Prog Med; 1993 Feb; 84(2):100-5. PubMed ID: 8465086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
    Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration.
    Campbell DB; Gordon BH; Ings RM; Richards R; Taylor DW
    Clin Neuropharmacol; 1988; 11 Suppl 1():S160-72. PubMed ID: 3052814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
    Zelissen PM; Stenlof K; Lean ME; Fogteloo J; Keulen ET; Wilding J; Finer N; Rössner S; Lawrence E; Fletcher C; McCamish M;
    Diabetes Obes Metab; 2005 Nov; 7(6):755-61. PubMed ID: 16219020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour.
    Mathus-Vliegen EM; van de Voorde K; Kok AM; Res AM
    J Intern Med; 1992 Aug; 232(2):119-27. PubMed ID: 1506807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. INDEX (international dexfenfluramine study) as a model for long-term pharmacotherapy of obesity in the 1990s.
    Guy-Grand B
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S5-14. PubMed ID: 1338322
    [No Abstract]   [Full Text] [Related]  

  • 34. Relative unresponsiveness of obese diabetic compared to obese non-diabetic subjects to the weight-reducing effect of fenfluramine.
    Otim MA
    East Afr Med J; 1977 Feb; 54(2):91-5. PubMed ID: 885093
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of withdrawal and re-introduction of dexfenfluramine in the treatment of obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    Int J Obes Relat Metab Disord; 1996 Mar; 20(3):280-2. PubMed ID: 8653152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fenfluramine and methylcellulose in the treatment of obesity: the relationship between plasma drug concentrations and therapeutic efficacy.
    Hossain M; Campbell DB
    Postgrad Med J; 1975; 51 Suppl 1(593):178-82. PubMed ID: 768965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial of fenfluramine in the treatment of obesity in Thai people.
    Chandraprasert S; Israsena T
    Mod Med Asia; 1977 Dec; 13(12):10-2. PubMed ID: 604778
    [No Abstract]   [Full Text] [Related]  

  • 38. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.
    Goodall E; Oxtoby C; Richards R; Watkinson G; Brown D; Silverstone T
    Br J Psychiatry; 1988 Aug; 153():208-13. PubMed ID: 2908235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Is fenfluramine a suitable therapeutic principle in obese aged diabetics?].
    Förster H; Huth K; Koch E; Tunali G
    Fortschr Med; 1979 Jan; 97(4):169-74. PubMed ID: 422110
    [No Abstract]   [Full Text] [Related]  

  • 40. Prolonged action fenfluramine in general practice.
    Owen JH
    Br J Clin Pract; 1975 Jan; 29(1):13-14. PubMed ID: 1095043
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.